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Objectives: To develop and optimize quantitative HPLC method using 2,3-
naphthalenedicarboxaldehyde (NDA) after simple and efficient solid phase
extraction to determine the histamine in a biopharmaceutical (Histobulin).
Methods: The HPLC method was established using NDA-induced Histobulin and
compared with the recently reported HPLC method using o-phthaldehyde (OPA).
The validated NDA-applied HPLC method was adjusted to 15 lots of Histobulin
and compared by the current lot-release-test method using fluorimetry in
recovery of histamine and reproducibility.
Results: Analyses of six HPLC chromatograms using NDA and OPA each were
compared. NDA produced a more stable chromatogram baseline than OPA, and
showed better stability. The HPLC analysis was validated in accuracy (91e103%),
precision (interday/intraday assay CV 2.30%), and linearity of doseeresponse
curve (R2  0.9919). The detection limit was 0.0076 mg/mL and the quantitative
limit was 0.0229 mg/mL. The amount of histamine per 12 mg of immunoglobulin
was determined to be 0.17  0.016 mg by the HPLC and 0.025  0.013 mg by the
current lot-release-test method using fluorimetry.
Conclusion: NDA derivatization showed better stability compared with the
OPA method. Therefore the newly established NDA-derivatizated HPLC method
may be more suitable than the fluorimetric method in lot-release-tests of
biopharmaceuticals.an@korea.kr (S.J. Ban).
ibuted under the terms of the Creative Commons Attribution Non-Commercial License
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Allergy is one of the most prevalent diseases
worldwide. More than half (54.6%) of all US citizens
test positive to 1 allergen [1], and 300 million people
worldwide have asthma, with 250,000 annual deaths
attributed to the disease [2]. As a therapeutic agent
against allergy, histamine-fixed immunoglobulin (Ig)
preparation has been used for bronchial asthma, allergic
rhinitis, and atopic dermatitis [3e6].
The histamine-fixed Ig preparation Histobulin
(Green Cross PD, Korea) comprises 0.15 mg of hista-
mine dihydrochloride and 12 mg of IgG. Histobulin was
developed from histamine-fixed serum that was able to
inhibit antigen-induced histamine release from human
peripheral blood basophils and rat peritoneal mast cells
[7,8]. Some scholars assumed that the histamine from
the Ig induces antihistamine antibody, so as to provide
resistance after allergen challenge [3].
However, excessive administration of histamine may
cause hypotension or hypertension, headaches, or
anaphylactic shock syndrome [9]. Therefore the hista-
mine content in the pharmaceutical should be controlled
by regulation. Since the Ig of Histobulin is derived from
human blood plasma, it is regulated by national
authority as a biological that should pass the lot-release
test before marketing [10]. Therefore development of
a validated quantitative method for the quantification of
histamine in Histobulin is very important for quality
control of the drug to increase safety. Besides the safety
aspect, Histobulin does not have a potency test; there-
fore, histamine quantification can also serve as potency
test related to the efficacy of the drug.
Analysis of histamine is mainly based on chromato-
graphic methods such as thin-layer chromatography
(TLC), capillary electrophoresis (CE), and high-
performance liquid chromatography (HPLC) [11]. The
current method for histamine detection of preparations in
lot-release test (specification: histamine should be
<0.5 mg/12 mg Ig) uses o-phthaldehyde (OPA)-derivat-
ized histamine detection by fluorimetric method or TLC
after serial solvent extraction of Histobulin. However,
these analyses have low accuracy and specificity.
Therefore HPLC methods have mainly been used for
histamine quantification, because they provide good
specificity and sensitivity when coupled with a highly
sensitive detector. Whereas histamine does not have UV-
visible absorbance in its chemical structure, derivatiza-
tion with fluorogenic reagents is the popular way to detect
it by fluorescence detector with HPLC, which can
improve the detection limit compared with the current
test methods for the national lot-release test mentioned
above. Therefore the majority of histamine assays employ
fluorometric detection with pre- or post-column deriva-
tization [12,13] using dansyl chloride [13,14], fluoresc-
amine [14], and OPA as labeling agents [15e17].Recently, a new analytical method including sepa-
ration of histamine from pharmaceutical matrices using
a polystyrene-divinylbenzene (PS-DVB) polymer and
subsequent pre-column derivatization with OPA prior to
HPLC analysis was reported [18]. However, OPA
derivatization of the preparation may not have enough
stability to adjust national lot-release test [19]. There-
fore the aim of this study was to develop an HPLC
method using the novel fluorescent derivatizing agent
2,3-naphthalenedicarboxaldehyde (NDA) and to opti-
mize the analytical conditions, including extraction
column selection and steps to improve sensitivity and
reproducibility compared with OPA-derivatized hista-
mine HPLC analysis. In addition, this study compared
the current lot-release test methods, TLC and fluorim-
etry, with the new HPLC method for application to the
national lot-release test. The HPLC method was also
validated following FDA guidelines for validation of
analytical assays [20].2. Materials and Methods
2.1. Materials and reagents
Histamine dihydrochloride (2-[4-imidazole]ethyl-
amine $ dihydrochloride, C5H9N3 $ 2HCl; FW, 184.1),
2-mercaptoethanol, 3-methyl-histamine dihydrochloride
(C6H11N32H Cl; FW, 198.1), sodium hydroxide, OPA
(C8H6O2; FW, 134.13), and NDA (C12H8O2; FW, 184.2)
were purchased from Sigma-Aldrich Co. (St. Louis,
MO, USA). HPLC-grade acetonitrile and methanol were
supplied by Fisher Scientific (Fair Lawn, NJ, USA). The
reagents used for HPLC mobile phase were used as
HPLC grade. All chemicals and reagents of analytical
grade were used without further purification. Deionized
water (DIW) was obtained from a Milli-Q water puri-
fication system (Millipore, Bedford, MA, USA). The Ig
pharmaceutical (Histobulin), human gamma-Ig with
histamine and matrix compositions, was provided by
Green-Cross PD Co. (Oh Chang, Chung Buk Province,
Korea). One vial of Histobulin comprises 12 mg of
lyophilized human IgG (hIgG) and 0.15 mg of histamine.
Other ingredients include sodium chloride (isotonic
agent, 4 mg), glycine (stabilizer, 45 mg), D-mannitol
(builder, 4 mg), and sodium hydroxide (pH adjuster,
trace amount). The blank matrix included the same
composition with the pharmaceutical except histamine.
Two reverse-phase solid-phase extraction (SPE)
cartridges with styrenedivinylbenzene (SDB)-coated
resin, Strata SDB-L (500 mg; particle size, 83 mm; pore
size, 260A˚, surface area, 500 m2/g), Strata SDB-X
(500 mg; particle size, 33 mm; pore size, 85A˚; surface
area, 800 m2/g), and one cation exchange SPE cartridge,
Strata SDB-X-CW (500 mg; 3 mL; particle size, 33 mm;
pore size, 85A˚; surface area, 800 m2/g) were purchased
from Phenomenex Co. (Torrance, CA, USA).
CHO
CHO
+ R-NH2
Histamine
CN-
pH 10
CN
N R
+ R-NH2
Histamine
CHO
CHO Beta-Mercapto-
-ethanol
N
S OH
R
COO-
A
B
Scheme 1. Derivatization reaction schemes of OPA (A) and
NDA (B) with histamine.
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The HPLC system was the Waters 2695 separation
module equipped with a Waters 2475 multi-l fluores-
cence detector (Milford, MA, USA) and a CH-150
column oven (Eldex Lab, CA, USA). Injected samples
were separated on a Lunaphenylhexyl analytical
column (5 mm; 103 A 250  4.6 mm i.d.; Phenomenex)
preceded by a phenyl guard column (3.0  4.0 mm i.d.;
Phenomenex). The HPLC software was DsChrom (ver.
2000 Net, Donam Inst., Seoul, Korea). Shimadzu
RF-1501 spectro-fluoro-photometer (Tokyo, Japan) or
Perkin Elmer LS 45 fluorescence spectroscopy (Perkin
Elmer, Waltham, MA, USA) was used for fluorimetry.
2.3. Standards preparation
Histobulin was reconstituted with 1 mL of water for
injection (WFI) per vial then were added 150 mL of
3-methylhistamine $ 2HCl, internal standard (IS; 1 mg/
mL), and 170 mL of 1 N sodium hydroxide to adjust to pH
9.5 followed by adding DIW to make final volume 2 mL.
Histamine $ 2HCl was diluted to 0, 25, 50, 75, 100, and
150 ng/mL with 100 mM sodium acetate, pH 9.5, con-
taining 150 ng of 3-methylhistamine $ 2HCl as IS.
2.4. Solid-phase extraction and sample
preparation
Three SPE cartridges were washed with 2 mL
methanol three times followed by three times of 2 mL
DIW rinsing. Each concentration of standards or sample
solution was loaded to rinsed SPEs by gravity. The vials
of standard or sample were rinsed with 1 mL of DIW
then loaded to the cartridges to bed volume (1.2 mL).
The columns were washed with 2 mL of DIW three
times followed by 1 mL of 40% (v/v) methanol in DIW
washing three times. Then, the cartridges were eluted
with 2 or 5 mL of 100 mM sodium acetate, pH 9.5, and
methanol (20% v/v). The histamine-containing eluent
was used for derivatization reaction.
2.5. Derivatization reaction
For NDA-fluorescent labeling, 0.6 mL of extract of
standard or sample was mixed with 0.2 mL borate
buffer, pH 9.5, with 10% (v/v) acetonitrile, then 0.2 mL
of 20 mM sodium cyanide solution was added and the
mixture vortexed for 1 minute. The mixture reacted with
0.4 mL of NDA (0.3 mM in methanol) at room
temperature for 4 hours because of relatively slow
reaction [19,21] (Scheme 1). After the reaction, 50 mL of
aliquots were injected into the HPLC system. For OPA-
derivatization of histamine in the extracts, 20 mg of
OPA was dissolved in 1 mL ethanol and 20 mL of
2-mercaptoethanol was added to the solution. Then,
100 mM borate buffer, pH 9.5, was added to the OPA-
containing solution to make a final volume of 20 mL
(OPA solution). OPA solution of 0.4 mL was added to
1.6 mL of standard or sample extracts and mixed
vigorously for 30 seconds [18].2.6. HPLC analysis
HPLC separation was performed on a reversed-phase
phenyl-hexyl column (4.6  250 mm; particle size,
5 mm; Phenomenex) kept at 40C using a mobile phase
consisting of acetonitrileephosphate buffer (pH 6.8;
50 mM) (35:65 v/v) at flow rate 1 mL/minute for OPA
and 2 mL/minute for NDA with 50 mL sample injection.
Fluorescence detection was achieved for OPA and NDA
at excitation maximum of 340 and 424 nm and emission
maximum 450 and 484 nm, respectively. The chro-
matogram peak area of histamine from standard and
samples to the area of internal standard was calculated
to determine histamine content.
2.7. Fluorimetry analysis
Fluorimetry followed a modified method of Glick
et al [22]. Briefly, histamine standard solution (15 mg/
mL in DIW) was diluted to 0, 0.15, 0.3, and 0.6 mg/mL
with DIW. Three vials of Histobulin were recon-
stituted with 1 mL DIW, then pooled (total volume,
3 mL). After serial extraction steps with organic
solvents, 2.5 mL of water layer in the bottom of the
solution was collected then were added 0.14 mL 4 N
hydroxide and 0.1 mL OPA (1 mg/mL in methanol) and
reacted in the dark for 5 minutes. To stop the reaction
0.28 mL of 42% citric acid was added. The reactant was
read by fluorescence spectroscopy at 360 nm excitation
maximum and 450 nm emission maximum to determine
histamine concentration in the sample from the standard
doseeresponse curve.3. Results and Discussion
3.1. Sample cleanup by various SPE cartridges
The biggest difficulty encountered for histamine
analysis of pharmaceuticals is the complexity of the real
drug matrix and the quite low amounts of histamine to
be monitored. In Histobulin, glycine is used as stabi-
lizer, which has an amine in the molecule that can react
with fluorescent materials, causing low reproducibility
in the analysis. Therefore pre-column derivatization can
be an effective solution not only to remove the matrix
signal, but also to determine submicro amounts of
histamine in the drug that affect the fluorogenic labeling
Table 1. Effect of reduced extraction volume in SPE
cartridge on HPLC analysis of histamine and
internal standard in human immunoglobulin
spiked with 0025 mg of histamine (n Z 6)
Extraction
volume Recovery (%) Histamine area IS area
2 mL 111.72e112.92 19.12e20.16 29.63e30.88
5 mL 108.63e115.92 9.69e10.60 14.45e14.54
130 J.-H. Kim, et alreaction. Accordingly, separation of the submicro
amounts of histamine (0.15 mg) from the main compo-
nents, glycine (45 mg) and Ig (12 mg), which can also
react with fluorogenic reagents, is critical in terms of
adequate recovery prior to HPLC analysis.
Although many cleanup procedures can be used for
isolation of biogenic amines from samples with complex
matrices, the C18-bonded silica SPE cartridge has been
widely used for trace enrichment of nonpolar and
moderately polar solutes. Recently, Kim et al. [18]
reported that SDB-L SPE was simple to use, stable
in alkaline pH, and effective to separate organicFigure 1. Representative chromatograms of HPLC with OPA-
3-methyl histamine (IS). (B) Histamine-added pharmaceuticals extcompounds from hydrophilic samples; sample pH 9e10
was optimal in extraction yield (>90%). In this study,
we used three types of SPE to increase recovery and
decrease other matrices in the eluent, including glycine,
which can be conjugated with fluorescent signal gener-
ator in the next step. SDB-L showed 73.7% recovery of
histamine and 74.0% of 3-methyl-histamine as an
internal standard, which was similar to a previous study
[18]. Comparable results were observed when the
polymeric sorbent surface-modified SDB-X extraction
was used. The recovery of SDB-X to histamine and 3-
methyl-histamin was determined as 74.4% and 85.9%,
respectively. However, polymeric sorbent surface-
modified SDB-X-CW did not show good recovery
yield (data not shown). Although polymeric sorbent
SDB-L and SDB-X showed similar recovery, SDB-L
had a shorter extraction time. Therefore we determined
that SDB-L was optimal for the separation. From the
results, it was concluded that histamine interacted
strongly with SDB-L sorbent and SDB-X even if they
existed in free base or singly charged form between pH
9e10 according to its pK values. To increase sensitivity
of histamine in HPLC analysis, the concentration of
eluent was optimized. The elution volume at thelabeled histamine. (A) Standard solutions of histamine and
racted by SDB-L SPE and (C) by SDB-X SPE.
Figure 2. HPLC chromatograms of different fluorescent labeling agents: (A) OPA; and (B) NDA. Six different concentrations of
histamine-containing samples with IS were analyzed and the chromatograms overlapped after each fluorescent agents’ derivatization.
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which was used in a previous study [18]. Comparing
HPLC analyses of the extracted samples with elution
volume of 2 and 5 mL, the 2-mL eluent showed more
than twice the increase in sensitivity of histamine and IS
in a chromatogram with OPA as the labeling agent
(Table 1, Figure 1). Additional washing solution after
2 mL elution did not show any histamine peak in the
chromatogram of HPLC, suggesting that our system
maintained histamine recovery even though the elution
volume was reduced to a minimum. Most of the Ig of
large molecular size washed out during the initial
washing step. Meanwhile, histamine was strongly
retained in the SPE sorbent phase during the washing
steps, whereas almost all histamine was eluted in small
volumes (approximately 2 mL) of eluent.Table 2. Recovery of histamine in matrix samples
prepared by spiking different concentrations of
histamine with 0.075 mg/mL of IS
Spiked
amount
(mg)
Final
conc.
(mg/mL)
HPLC analysis
result
(mg/mL)
RSD
(%)
Recovery
(%)
0.05 0.025 0.0258  0.0008 3.27 103.2
0.10 0.050 0.0490  0.0019 3.85 97.9
0.15 0.075 0.0713  0.0024 3.34 95.0
0.20 0.100 0.0916  0.0017 1.89 91.6
0.30 0.150 0.1525  0.0014 0.94 101.7
Mean  SD (n Z 6).
RSD Z relative standard deviation.3.2. Comparison of fluorescent labeling agents
OPA with NDA in histamine derivatization
Histamine and OPA reacted faster than NDA in the
presence of 2-mercaptoethanol as co-ligand [18].
However, the stability of OPA is questionable, which
might affect reproducibility of the assay [19,23]. There-
fore we selected NDA as an alternative fluorescent agent;
NDA produced an improved chromatogram with stable
baseline and retention time within the target in our system
(Figure 2), but longer reaction time was needed because
of the relatively slow chemical reaction [19]. However,
the longer reaction time (4 hours at room temperature) did
not affect any factors in point-of-method validation, such
as specificity, accuracy, and precision. The chromato-
gram baseline around the histamine peak, which might
affect sensitivity of the analysis, was stabilized when
NDA was used as a fluorescent labeling agent because of
reduced byproducts formation, whereas OPA gave some
byproduct peaks around the histamine peak and relatively
unstable baselines during 6 samples analyses period,
because of instability of OPA (Figure 2). These findings
made us decide that NDA was the optimal fluorescent
agent in this derivatization step.
3.3. HPLC analysis
Due to the optimization of eluent concentration in
the extraction step, the detection limit of histamine was
lowered to 7.58 ng/mL using NDA-labeled samples on
reversed-phase HPLC with isocratic elution of the
mobile phase of acetonitrileephosphate buffer (pH 6.8;
Table 3. Intra-day and inter-day analyses of HPLC using NDA-labeled histamine in matrix sample prepared by spiking
histamine with 0.075 mg/mL of IS
Histamine spiked
(mg)
Histamine concentration
(mg/mL) Day
Histamine conc.
(mg/mL)
RSD
(%)
Recovery
(%)
0.15 0.075 1 0.0747  0.0004 0.51 99.59
0.15 0.075 2 0.0777  0.0004 0.56 103.61
0.15 0.075 3 0.0784  0.0011 1.40 104.47
Mean  SD (n Z 6).
RSD Z relative standard deviation.
132 J.-H. Kim, et al50 mM) (35:65 v/v). In the preliminary study, we
compared methanol versus acetonitrile as the mobile
phase with a 0.5e2 mL/minute flow rate. However,
methanol and the slower flow rate gave lower sensitivity
and an inapplicable detection limit (data not shown)
when NDA was utilized as a fluorescent derivatizer.
Therefore 35% acetonitrile with 2 mL/minute was
decided to be optimal. The mean retention time of
histamine was 8.80  0.1 minutes for OPA-labeled
histamine and 11.80  0.001 minutes for NDA-labeled
histamine. IS retention time for OPAe and NDA-labeled
IS was 11.07  0.1 and 16.70  0.001 minutes, respec-
tively, which also showed complete baseline separation
with histamine in both fluorescents (Figure 2). The HPLC
retention time of OPA-labeled histamine and IS was
similar to that in the previous report [18].
3.4. Validation of HPLC analysis
Using this optimized NDA-derivatized histamine
analysis method, validation tests were performed with
histamine-spiked matrix solution, including accuracy,
precision, linearity, specificity, and detection limit,. The
accuracy test used histamine (0.025, 0.05, 0.075, 0.10,
and 0.15 mg/mL)-spiked matrix solution with 0.15 mg/
mL IS. Recovery was 90e105% at each concentration;
relative standard deviation (RSD) was <4.0% (Tables 2
and 3) and R2 of the doseeresponse curve was >0.992
(Table 4), which was comparable to the control solution
with the same range of histamine-added matrix solution
(R2 Z 0.992; n Z 3). The histamine concentration of
Histobulin is 0.075 mg/mL. Therefore histamine in the
pharmaceutical can be quantitatively determined by this
doseeresponse curve. Day-to-day analysis for 3 days
(n Z 6 per day) showed good intraday and interday
precision (RSD <2%) (Table 3). Therefore theTable 4. Linearity of doseeresponse curves of HPLC analysis
HPLC analysis R2
Day 1 0.9950
Day 2 0.9916
Day 3 0.9928
Mean  SD 0.9931  0.0017
SD Z standard deviation.accuracy, linearity, and repeatability of the analysis
were validated. Using 0.075 mg/mL of IS only and
histamine standard-spiked solution revealed baseline
separated peaks in HPLC, suggesting that this system
had good specificity. Based on the above reproducibility
assessment data, detection limit and range was deter-
mined. The equation (10  b)/S was used for quanti-
zation limit and (3.3  b)/S for detection limit, where b
is the standard deviation of intercept and S the average
of the slope of the doseeresponse curve based on
accuracy test. Quantitative limit and detection limit were
determined as 0.0229 and 0.0076 mg/mL, respectively;
both were in the targeted range 0.025e0.15 mg/mL. This
doseeresponse curve can be used for quantification of
histamine in pharmaceuticals.
3.5. Comparison of histamine content test from
Histobulin for lot-release test
Current lot-release test methods for Histobulin, TLC
and fluorimetry were compared with HPLC analysis of
histamine from Histobulin using NDA as the fluorescent
agent. With 15 lots of Histobulin as samples, an
average of 0.17  0.016 mg/12 mg Ig per vial (range,
0.15e0.21 mg/vial) was determined by HPLC analysis.
Meanwhile the fluorimetry method produced a result of
0.025  0.013 mg/vial (range, 0.0045e0.0454 mg/vial;
Figure 3). The TLC method only provided a qualitative
analysis. The amount of histamine in the pharmaceutical
satisfied the current specification (<0.5 mg/vial) in both
analyses. However, that from the new HPLC method
resulted in a slightly higher than expected amount
(0.15 mg/vial). Therefore we plan to investigate the
reason for this with the manufacturer of Histobulin as
a further study, to set new specifications for histamine in
this pharmaceutical.for NDA-labeled histamine on days 1e3
Dose response curve parameters
Slope Intercept
0.0245 0.1880
0.0243 0.1930
0.0277 0.0892
0.0255  0.0019 0.1567  0.0585
Figure 3. Comparison of analytic methods of histamine
using 15 lots of histamine-added human immunoglobulin:
current lot-release test method using fluorometry (red squares)
and new HPLC method (blue diamonds) are shown. For HPLC
method, n Z 3; Bars, SD.
Figure 4. Trend analysis of histamine content in 15 lots of
human immunoglobulin preparations with histamine.
Mean  SD was 0.168  0.016 mg/vial. 2SD and 4SD lines are
shown as dotted lines.
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The histamine quantification method using HPLC
after pre-column extracted Ig preparation with NDA
derivatization was optimized and validated. NDA utilized
HPLC method for histamine quantification in the prepa-
ration may compensate current test method for histamine
detection which has complicate extract steps resulting
inaccurate results frequently. This method will soon be
applied to the national lot-release test and the specifica-
tion of histamine content in pharmaceuticals including
histamine-added hIg will be set with the accumulated lot-
release test based on standard deviation ranges (Figure 4).
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